BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 37185443)

  • 1. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
    Verma S; Breadner D; Raphael J
    Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
    Parisi C; Mahjoubi L; Gazzah A; Barlesi F
    Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
    Desai A; Abdayem P; Adjei AA; Planchard D
    Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
    Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
    Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class.
    Marks JA; Wilgucki M; Liu SV; Reuss JE
    Curr Oncol Rep; 2022 Dec; 24(12):1829-1841. PubMed ID: 36197593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC).
    Abuhelwa Z; Alloghbi A; Nagasaka M
    Cancer Treat Rev; 2022 May; 106():102393. PubMed ID: 35472631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.
    Liu X; Deng J; Zhang R; Xing J; Wu Y; Chen W; Liang B; Xing D; Xu J; Zhang M
    Front Immunol; 2023; 14():1335252. PubMed ID: 38162667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
    Fenton MA; Tarantino P; Graff SL
    Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach.
    Marks S; Naidoo J
    Lung Cancer; 2022 Jan; 163():59-68. PubMed ID: 34923203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.
    Nelson BE; Meric-Bernstam F
    Annu Rev Med; 2024 Jan; 75():31-48. PubMed ID: 37758237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioneering the Way: The Revolutionary Potential of Antibody-Drug Conjugates in NSCLC.
    Chen X; Zeng C
    Curr Treat Options Oncol; 2024 Apr; 25(4):556-584. PubMed ID: 38520605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
    Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
    Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Drug Conjugates for Breast Cancer.
    Marmé F
    Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?
    Zardavas D
    Expert Opin Investig Drugs; 2022 Jun; 31(6):633-644. PubMed ID: 35451891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates in solid tumors: a look into novel targets.
    Criscitiello C; Morganti S; Curigliano G
    J Hematol Oncol; 2021 Jan; 14(1):20. PubMed ID: 33509252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
    von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
    Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
    Peters S; Loi S; André F; Chandarlapaty S; Felip E; Finn SP; Jänne PA; Kerr KM; Munzone E; Passaro A; Pérol M; Smit EF; Swanton C; Viale G; Stahel RA
    Ann Oncol; 2024 Apr; ():. PubMed ID: 38648979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies.
    Tarantino P; Carmagnani Pestana R; Corti C; Modi S; Bardia A; Tolaney SM; Cortes J; Soria JC; Curigliano G
    CA Cancer J Clin; 2022 Mar; 72(2):165-182. PubMed ID: 34767258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.